246 related articles for article (PubMed ID: 27984399)
1. Accuracy of Consecutive Fecal Calprotectin Measurements to Predict Relapse in Inflammatory Bowel Disease Patients Under Maintenance With Anti-TNF Therapy: A Prospective Longitudinal Cohort Study.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
J Clin Gastroenterol; 2018 Mar; 52(3):229-234. PubMed ID: 27984399
[TBL] [Abstract][Full Text] [Related]
2. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
[TBL] [Abstract][Full Text] [Related]
3. Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Otero Santiago M; Lorenzo Gonzalez A; Alonso de la Peña C; Benitez Estevez AJ; Dominguez-Muñoz JE
J Clin Gastroenterol; 2016 Feb; 50(2):147-51. PubMed ID: 25811118
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
[TBL] [Abstract][Full Text] [Related]
5. Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
Monteiro S; Dias de Castro F; Leite S; Moreira MJ; Cotter J
Scand J Gastroenterol; 2019 Jan; 54(1):49-54. PubMed ID: 30663515
[TBL] [Abstract][Full Text] [Related]
6. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
[TBL] [Abstract][Full Text] [Related]
7. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn's disease patients.
Foster AJ; Smyth M; Lakhani A; Jung B; Brant RF; Jacobson K
World J Gastroenterol; 2019 Mar; 25(10):1266-1277. PubMed ID: 30886509
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease.
Naismith GD; Smith LA; Barry SJ; Munro JI; Laird S; Rankin K; Morris AJ; Winter JW; Gaya DR
J Crohns Colitis; 2014 Sep; 8(9):1022-9. PubMed ID: 24566170
[TBL] [Abstract][Full Text] [Related]
9. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
[TBL] [Abstract][Full Text] [Related]
10. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
[TBL] [Abstract][Full Text] [Related]
11. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice.
Pauwels RWM; de Vries AC; van der Woude CJ
J Gastroenterol Hepatol; 2020 Nov; 35(11):1893-1901. PubMed ID: 32291796
[TBL] [Abstract][Full Text] [Related]
12. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
[TBL] [Abstract][Full Text] [Related]
13. Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.
Diederen K; Hoekman DR; Leek A; Wolters VM; Hummel TZ; de Meij TG; Koot BG; Tabbers MM; Benninga MA; Kindermann A
Aliment Pharmacol Ther; 2017 Apr; 45(7):951-960. PubMed ID: 28138990
[TBL] [Abstract][Full Text] [Related]
14. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists.
Tursi A; Elisei W; Picchio M; Giorgetti G; Brandimarte G
Dig Dis Sci; 2015 May; 60(5):1406-13. PubMed ID: 25445163
[TBL] [Abstract][Full Text] [Related]
16. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
17. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
18. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
[TBL] [Abstract][Full Text] [Related]
19. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
[No Abstract] [Full Text] [Related]
20. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
van Rheenen PF
Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
